A class of drugs called glucagon-like peptide agonists (GLP-1 agonists) is proving to be beneficial for people with chronic kidney disease and atherosclerotic heart disease. These medications are being called game changers because they not only help with weight loss but also provide organ protection and reduce the risk of dying and disease progression.��

These medications have the potential to revolutionize the treatment of deadly conditions and improve population health. However, there are financial pressures and healthcare policies that may hinder access to these medications for patients who could benefit from them.��

On today's program, host Sean Collins talks with two Physician-Researchers working on the front lines of the coming change.

.

.

Katherine R. Tuttle, M.D., FASN, FACP, FNKF
Executive Director for Research, Providence Inland Northwest Health
Professor of Medicine, Division of Nephrology and Kidney Research Institute
Regional Principal Investigator, Institute of Translational Health Sciences
University of Washington

.

Radica Alicic, M.D., FHM, FACP

Associate Director for Research

Providence Health Care in Spokane

.

.

Management of Chronic Kidney Disease in People with Diabetes��

Read more about Retatrutide, the triple agonist

��